Recent advances of siRNA delivery by nanoparticles

Xudong Yuan, Sandy Naguib, Zhiqian (James) Wu

Research output: Contribution to journalArticlepeer-review

Abstract

Introduction: The field of RNA interference technology has been researched extensively in recent years. However, the development of clinically suitable, safe and effective drug delivery vehicles is still required.

Areas covered: This paper reviews the recent advances of non-viral delivery of small interfering RNA (siRNA) by nanoparticles, including biodegradable nanoparticles, liposomes, polyplex, lipoplex and dendrimers. The characteristics, composition, preparation, applications and advantages of different nanoparticle delivery strategies are also discussed in detail, along with the recent progress of non-viral nanoparticle carrier systems for siRNA delivery in preclinical and clinical studies.

Expert opinion: Non-viral carrier systems, especially nanoparticles, have been investigated extensively for siRNA delivery, and may be utilized in clinical applications in the future. So far, a few preliminary clinical trials of nanoparticles have produced promising results. However, further research is still required to pave the way to successful clinical applications. The most important issues that need to be focused on include encapsulation efficiency, formulation stability of siRNA, degradation in circulation, endosomal escape and delivery efficiency, targeting, toxicity and off-target effects. Pharmacology and pharmacokinetic studies also present another great challenge for nanoparticle delivery systems, owing to the unique nature of siRNA oligonucleotides compared with small molecules.
Original languageAmerican English
JournalExpert Opinion on Drug Delivery
Volume8
DOIs
StatePublished - Jan 1 2011

Keywords

  • RNA interference
  • drug delivery
  • gene delivery
  • nanoparticle
  • non-viral vector
  • siRNA
  • Animals
  • Clinical Trials as Topic
  • Drug Carriers
  • Humans
  • Nanoparticles
  • RNA
  • RNA binding
  • RNA degradation
  • RNA induced silencing complex
  • RNA stability
  • Small Interfering
  • adenomatous polyp
  • aln vsp02
  • antiviral activity
  • arginylglycylaspartic acid
  • atu 027
  • azetidine
  • calaa 01
  • cancer gene therapy
  • cancer inhibition
  • carbosilane
  • chitosan
  • cisplatin
  • colorectal cancer
  • cyclodextrin
  • cytokine release
  • dendrimer
  • dextran
  • dose response
  • doxorubicin
  • drug clearance
  • drug cytotoxicity
  • drug half life
  • drug targeting
  • endosome
  • familial colon polyposis
  • fluorescence microscopy
  • gene silencing
  • gene targeting
  • genetic transfection
  • human
  • hypercholesterolemia
  • lamivudine
  • lipoplex
  • liposomal gene delivery system
  • liposome
  • liver cell carcinoma
  • liver metastasis
  • locked nucleic acid
  • lung metastasis
  • melanoma
  • mucoadhesion
  • multidrug resistance protein 1
  • nanoencapsulation
  • nasopharynx tumor
  • nonhuman
  • nonviral gene delivery system
  • pDrive sh AnxA2 plasmid DNA
  • paclitaxel
  • plasmid DNA
  • polycaprolactone
  • polyethyleneimine
  • polymerization
  • prostate tumor
  • review
  • short hairpin RNA
  • small interfering RNA
  • small interfering locked nucleic acid
  • solid lipid nanoparticle
  • solid tumor
  • static electricity
  • thyroid papillary carcinoma
  • transferrin
  • tumor necrosis factor alpha
  • unclassified drug
  • unspecified side effect
  • wound healing

Disciplines

  • Medicinal Chemistry and Pharmaceutics
  • Medicine and Health Sciences
  • Pharmacy and Pharmaceutical Sciences

Cite this